These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8687126)
1. C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases. Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G Anticancer Res; 1996; 16(2):765-71. PubMed ID: 8687126 [TBL] [Abstract][Full Text] [Related]
2. Proliferating cell nuclear antigen (PCNA) expression in patients with breast carcinoma in comparison to patients with benign breast diseases. Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G In Vivo; 1994; 8(6):1053-6. PubMed ID: 7772736 [TBL] [Abstract][Full Text] [Related]
3. P53 expression in patients with malignant and benign breast diseases. Kalogeraki A; Panayiotides J; Tamiolakis D; Tzardi M; Chaniotis V; Chalkiadakis G; Melissas J; Stiftsis D; Kanavaros P; Delides GS Anticancer Res; 2000; 20(3A):1801-5. PubMed ID: 10928110 [TBL] [Abstract][Full Text] [Related]
4. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index. Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249 [TBL] [Abstract][Full Text] [Related]
5. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma. Zheng WQ; Looi LM; Cheah PL Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions. Goussia A; Agnantis NJ; Athanassiadou S; Stefanou D Anticancer Res; 1995; 15(5B):2313-8. PubMed ID: 8572645 [TBL] [Abstract][Full Text] [Related]
7. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
8. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Sasano H; Frost AR; Saitoh R; Matsunaga G; Nagura H; Krozowski ZS; Silverberg SG Anticancer Res; 1997; 17(3C):2001-7. PubMed ID: 9216657 [TBL] [Abstract][Full Text] [Related]
9. Detection by immunohistochemistry of c-erbB2 oncoprotein in breast carcinomas and benign mammary lesions. Edorh A; Leroux A; N'sossani B; Parache RM; Rihn B Cell Mol Biol (Noisy-le-grand); 1999 Sep; 45(6):831-40. PubMed ID: 10541479 [TBL] [Abstract][Full Text] [Related]
10. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
11. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries. Gould VE; Mosquera JM; Leykauf K; Gattuso P; Dürst M; Alonso A Hum Pathol; 2005 May; 36(5):536-45. PubMed ID: 15948121 [TBL] [Abstract][Full Text] [Related]
12. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
13. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785 [TBL] [Abstract][Full Text] [Related]
14. Argyrophilic nucleolar organiser regions (AgNORs) in breast lesions. Dasgupta A; Ghosh RN; Sarkar R; Laha RN; Ghosh TK; Mukherjee C J Indian Med Assoc; 1997 Sep; 95(9):492-4. PubMed ID: 9529579 [TBL] [Abstract][Full Text] [Related]
15. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611 [TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782 [TBL] [Abstract][Full Text] [Related]
17. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Hanna W; Kahn HJ; Andrulis I; Pawson T Mod Pathol; 1990 Jul; 3(4):455-61. PubMed ID: 1977159 [TBL] [Abstract][Full Text] [Related]
18. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403 [TBL] [Abstract][Full Text] [Related]
19. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Chiappetta G; Botti G; Monaco M; Pasquinelli R; Pentimalli F; Di Bonito M; D'Aiuto G; Fedele M; Iuliano R; Palmieri EA; Pierantoni GM; Giancotti V; Fusco A Clin Cancer Res; 2004 Nov; 10(22):7637-44. PubMed ID: 15569996 [TBL] [Abstract][Full Text] [Related]
20. p53 expression in cytologic specimens from benign and malignant breast lesions. Koutselini H; Malliri A; Field JK; Spandidos DA Anticancer Res; 1991; 11(4):1415-9. PubMed ID: 1746898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]